Close of Bookbuild

Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company, is pleased to announce that, further to the announcements made on 30 November 2023 and 1 December 2023, the Bookbuild has now closed.

The Company has successfully raised approximately £2.5 million via binding participations in the Placing and the Subscription. Participants in the Placing will be contacted by Singer Capital Markets Securities Limited ("SCM") or RBC Capital Markets ("RBC", and together with SCM, the "Joint Bookrunners") as soon as practicable to confirm their allocations. A further announcement will be made in due course confirming details of the Placing.

The Company had previously announced a broker option in connection with the Fundraising, which was intended to allow other institutional investors and Relevant Persons to participate. The aggregate Fundraising had been capped at £2.5 million, but in light of the demand for the Placing and Subscription the Company intends to increase the overall Fundraising size, as commitments already received mean that there are insufficient shares to allocate to the Broker Option or to Employee Subscribers.

Further announcements will be made in due course.

Save as otherwise defined, capitalised terms used in this announcement have the meanings given to them in the announcement released by the Company on 30 November 2023.

Ondine Biomedical Inc.

UK Product Governance Requirements

EU Product Governance Requirements